The Kauffman Indicators of Entrepreneurship offers in-depth measures, reports, and accompanying interactive data visualizations that present entrepreneurial trends in the United States.
A life sciences-focused venture capital firm based near Boston has raised more than one-third of a billion dollars to invest in early-stage companies.
The Maryland Technology Development Corporation (TEDCO) announced today the formation of the Task Force for Women Entrepreneurs. The task force will be dedicated to the recruitment, funding, and operational support of women-owned and-led startups in Maryland.
When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover.
Amazon changed the rules of economic development when it announced a 50,000-job HQ2 sweepstakes in 2017. While most searches for large facilities happen behind closed doors, the Seattle tech giant kicked off an unprecedented, high-stakes, public battle for its next corporate home.
Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is now certified to offer a groundbreaking treatment for non-Hodgkin lymphoma, in which a patient’s own immune cells are genetically engineered to recognize and attack the cancer.
Maryland has the most computer and data scientists in the U.S., and the second-highest concentrations of engineers and life scientists.
Microsoft outlined how emerging technologies can support diagnosis of rare diseases among children in a report released Feb. 20.
Rare diseases affect almost 350 million people globally, and they can take an average of five years to diagnose, according to the report.
Under a new licensing deal, Qiagen will gain access to a big genetics database from Vienna-based Ares Genetics, which could help tackle the global health crisis of antibiotic resistance.